行情

VNDA

VNDA

万达生物制药
NASDAQ

实时行情|Nasdaq Last Sale

11.85
-0.08
-0.67%
盘后: 11.85 0 0.00% 16:00 07/02 EDT
开盘
12.09
昨收
11.93
最高
12.10
最低
11.64
成交量
26.29万
成交额
--
52周最高
17.85
52周最低
7.12
市值
6.46亿
市盈率(TTM)
5.54
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VNDA价格均价为17.00,最高价位25.00,最低价为13.00。

EPS

VNDA 新闻

更多
Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds Sticking Around
In this article we will check out the progression of hedge fund sentiment towards Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of
Insider Monkey · 06/19 18:38
Top Biotech Stocks for Q3 2020
Investopedia · 06/09 19:09
Top Biotech Stocks for Q3 2020
The biotechnology industry includes companies that develop drugs and diagnostic compounds for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Biotech
Investopedia · 06/09 18:09
Why Vanda's Stock Is Trading Lower Today
Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.
Benzinga · 06/09 14:51
Citigroup Downgrades Vanda Pharmaceuticals to Neutral, Announces $14 Price Target
Citigroup analyst Joel Beatty downgrades Vanda Pharmaceuticals (NASDAQ:VNDA) from Buy to Neutral and announces $14 price target.
Benzinga · 06/09 11:46
Healthcare And Biotechnology Dashboard - Update
Seeking Alpha - Article · 05/26 23:03
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") in a virtual-only format due to public health concerns related to the COVID-19 pandemic and to protect
PR Newswire · 05/26 11:00
Vanda Pharma Reports Federal District Court Granted Co. Motion To Dismiss False Claims Act Suit Filed Against Co.
Benzinga · 05/20 21:20

所属板块

生物技术和医学研究
+0.67%
制药与医学研究
+0.61%

热门股票

代码
价格
涨跌幅

VNDA 简况

Vanda Pharmaceuticals Inc.是一家生物制药公司。该公司专注于开发和销售用于治疗中枢神经系统(CNS)疾病的药品。该公司的产品组合包括HETLIOZ(他司美琼)、Fanapt(伊潘立酮)、Tradipitant(VLY-686)、曲古柳菌素A和AQW051。该公司提供用于治疗非24小时睡醒周期障碍(非24小时)的HETLIOZ(他司美琼)。该公司提供用于治疗精神分裂症的Fanapt(伊潘立酮)。此外,其分销合作伙伴在以色列和墨西哥推出Fanapt。Tradititant(VLY-686)是一种小分子神经激肽-1受体(NK-1R)拮抗剂,用于临床开发中治疗特应性皮炎的慢性瘙痒。曲古柳菌素A是小分子组蛋白脱乙酰酶(HDAC)抑制剂。AQW051是II期α-7烟碱型乙酰胆碱受体部分激动剂。它专注于治疗CNS疾病。
展开

微牛提供Vanda Pharmaceuticals Inc.(NASDAQ-VNDA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VNDA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易VNDA股票基本功能。